High Blood Pressure

Clinical Trial Finder

Many patients with high blood pressure are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)

Condition:   Pulmonary Arterial Hypertension
Intervention:   Drug: Remodulin® (Intravenous Treprostinil)
Sponsor:   United Therapeutics
Completed - verified February 2017

The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension

Conditions:   Pulmonary Hypertension;   Pulmonary Arterial Hypertension
Intervention:  
Sponsors:   University of Giessen;   Universitätsklinikum Hamburg-Eppendorf;   DRK Kliniken Berlin Köpenick, Berlin, Germany;   University Hospital, Zürich;   University Hospital Carl Gustav Carus
Recruiting - verified February 2017

Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)

Condition:   Pulmonary Hypertension Associated With HFpEF
Intervention:   Drug: Oral Treprostinil
Sponsor:   United Therapeutics
Not yet recruiting - verified February 2017

Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis

Condition:   Nephrolithiasis
Interventions:   Drug: Placebo oral capsule;   Drug: 12.5 mg hydrochlorothiazide;   Drug: 25.0 mg hydrochlorothiazide;   Drug: 50.0 mg hydrochlorothiazide
Sponsor:   University Hospital Inselspital, Berne
Not yet recruiting - verified February 2017

Fixed Combination for Lipid and Blood Pressure Control

Conditions:   Arterial Hypertension;   Dyslipidemias;   Blood Pressure;   Lipid Metabolism Disorders
Intervention:   Drug: Atorvastatin, Amlodipine, Perindopril
Sponsors:   Charles University, Czech Republic;   University Hospital Olomouc;   University Hospital Pilsen;   General Teaching Hospital, Prague;   St. Anne;   Brno University Hospital;   Na Homolce Hospital
Not yet recruiting - verified February 2017

Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)

Conditions:   Pulmonary Hypertension;   Heart Failure With a Preserved Ejection Fraction
Interventions:   Drug: Oral treprostinil;   Drug: Placebo
Sponsor:   United Therapeutics
Not yet recruiting - verified February 2017

Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

Condition:   Pulmonary Hypertension Associated With Sickle Cell Disease
Interventions:   Drug: Oral Treprostinil;   Drug: Placebo
Sponsor:   United Therapeutics
Not yet recruiting - verified February 2017

Invasive Validation of Non-invasive Central Blood Pressure Measurements Using Oscillometric Pulse Wave Analysis

Conditions:   Arterial Hypertension;   Coronary Heart Disease
Intervention:  
Sponsor:   Universitätsmedizin Mannheim
Active, not recruiting - verified February 2017

Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis

Condition:   Bronchiolitis
Interventions:   Drug: Nitric Oxide;   Other: Supportive treatment
Sponsor:   Advanced Inhalation Therapies Ltd
Not yet recruiting - verified February 2017

Assessment of Home Tonometry in Glaucoma

Conditions:   Glaucoma;   Intraocular Pressure
Intervention:   Device: iCare home tonometer
Sponsor:   NHS Lothian
Recruiting - verified February 2017

Genetic Determinants of ACEI Prodrug Activation

Condition:   Healthy Volunteers
Intervention:   Drug: Enalapril
Sponsor:   University of Michigan
Recruiting - verified February 2017

Stress Echo 2020 - The International Stress Echo Study

Conditions:   Coronary Artery Disease;   Heart Failure;   Hypertrophic Cardiomyopathy;   Aortic Valve Disease;   Athletes Heart;   Tetralogy of Fallot;   Pulmonary Arterial Hypertension
Interventions:   Procedure: Left ventricular contractile reserve SE;   Procedure: B-lines SE;   Procedure: Left ventricular outflow tract gradient SE;   Procedure: Diastolic function SE;   Procedure: Mitral regurgitation SE;   Procedure: Pulmonary hemodynamics SE;   Procedure: Coronary flow reserve SE
Sponsors:   Fatebenefratelli Hospital;   Institute of Clinical Physiology, CNR, Pisa,Italy;   Salerno Hospital, Italy;   Monaldi Hospital, Napoli, Italy;   University of Pisa, Italy;   San Luca Hospital, Lucca, Italy;   Careggi University Hospital, Florence, Italy;   Federico II University, Napoli, Italy;   San Carlo Hospital, Potenza, Italy;   Royal Brompton & Harefield NHS Foundation Trust;   Ospedale dell'Angelo, Venezia-Mestre, Italy;   University of Parma;   Hospital Clinics, Trieste, Italy;   Rio Grande do Sul University Hospital, Porto Alegre, Brasil;   Hospital San José, Criciuma, Brasil;   Hospital San Vicente de Paulo, Passo Fundo, Brasil;   University of Belgrade;   University of Szeged, Hungary;   Elisabeth Hospital, Hodmezovasarhely, Hungary;   University of Padua, Italy;   Sandro Pertini Hospital, Rome, Italy;   Medical Center Hospital of the Republic of Kazakhstan, Astana, Kazakhstan;   Hospital Clinics, Bari, Italy;   Ospedale Nottola, Siena, Italy;   University of Catania, Italy;   Medika Cardiocenter, Saint Petersburg, Russian Federation
Recruiting - verified February 2017

Effect of Total Intravenous Anaesthesia With Propofol on Postoperative Pain After Bilateral Third Molar Surgery

Condition:   Postoperative Pain
Interventions:   Drug: propofol;   Drug: Sevoflurane
Sponsor:   The University of Hong Kong
Active, not recruiting - verified February 2017

Non-invasive Validation of Non-invasive Central Blood Pressure Measurements Using Oscillometric Pulse Wave Analysis

Conditions:   Arterial Hypertension;   Healthy Control;   Coronary Heart Disease;   Diabetes Mellitus
Intervention:  
Sponsor:   Universitätsmedizin Mannheim
Recruiting - verified February 2017

Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Condition:   Non-arteritic Anterior Ischemic Optic Neuropathy
Interventions:   Drug: Group A Citicoline 1000 mg oral tablet;   Drug: Group B placebo oral tablet
Sponsor:   Valen Chia
Recruiting - verified February 2017

Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions

Condition:   Hypertension
Interventions:   Drug: GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets);   Drug: Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified February 2017

A Novel Approach for Transjugular Intrahepatic Portocaval Shunt Creation Using Real-time Three Dimensional Roadmap

Condition:   Portal Hypertension
Interventions:   Other: 3d roadmap guidance;   Other: conventional TIPS
Sponsor:   West China Hospital
Recruiting - verified February 2017

An Optical System for Measuring Blood Pressure

Condition:   Blood Pressure Disorders
Interventions:   Device: Blood pressure measurement;   Device: Blood pressure measurement with the new device
Sponsor:   Meir Medical Center
Not yet recruiting - verified February 2017

Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients

Condition:   Hypertension
Intervention:   Drug: S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet
Sponsor:   Neutec Ar-Ge San ve Tic A.Ş
Completed - verified February 2017

To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension

Condition:   Hypertension
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Condition:   Pulmonary Arterial Hypertension
Interventions:   Drug: Parenteral Remodulin (treprostinil) injection;   Drug: Oral Treprostinil
Sponsor:   United Therapeutics
Not yet recruiting - verified February 2017

To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis

Condition:   Associated Pulmonary Arterial Hypertension
Interventions:   Drug: Sildenafil 20mg and Bosentan 62.5mg;   Drug: Sildenafil 20mg and Placebo
Sponsor:   Postgraduate Institute of Medical Education and Research
Recruiting - verified February 2017

Improve Glaucoma Medication Adherence

Condition:   Glaucoma
Interventions:   Behavioral: Educational;   Behavioral: Dose reminder;   Behavioral: Educational;   Behavioral: dose monitoring
Sponsor:   VA Office of Research and Development
Not yet recruiting - verified February 2017

SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

Conditions:   Nocturnal Hypertension;   T2DM (Type 2 Diabetes Mellitus)
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Jichi Medical University;   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2017

Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome

Conditions:   Prostate Cancer;   Metabolic Syndrome
Interventions:   Drug: Metformin;   Drug: Placebo Oral Tablet
Sponsors:   Canadian Urologic Oncology Group;   Prostate Cancer Canada;   British Columbia Cancer Agency
Not yet recruiting - verified February 2017

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

Condition:   Pulmonary Arterial Hypertension
Interventions:   Drug: Oral Treprostinil;   Drug: Placebo
Sponsor:   United Therapeutics
Not yet recruiting - verified December 2016

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

Conditions:   Pulmonary Hypertension;   Chronic Obstructive Pulmonary Disease
Intervention:   Drug: Inhaled Treprostinil
Sponsor:   United Therapeutics
Not yet recruiting - verified February 2017

Nocturnal Hypertension and Nocturia in African American Men

Condition:   Hypertension
Intervention:  
Sponsor:   Cedars-Sinai Medical Center
Not yet recruiting - verified February 2017

A Phase 2/3 Trial of the the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL

Condition:   Alport Syndrome
Interventions:   Drug: Placebo Oral Capsule;   Drug: Bardoxolone Methyl
Sponsor:   Reata Pharmaceuticals, Inc.
Recruiting - verified February 2017

Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives

Condition:   Hypertension
Interventions:   Drug: Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule;   Drug: Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule;   Drug: Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule
Sponsor:   Kitov Pharmaceuticals, Ltd.
Recruiting - verified February 2017

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Condition:   Metabolic Syndrome
Intervention:   Drug: 3-V Bioscience-2640
Sponsors:   University of Missouri-Columbia;   3V Biosciences, Inc.
Recruiting - verified October 2016

Evaluation of an Electronic CKD Clinical Decision Support System (CDSS) in Clinical Care

Conditions:   Hypertension;   Renal Insufficiency, Chronic
Interventions:   Other: Clinical Decision Support System (CDSS);   Other: Clinic Decision Sup System + Pharmacist
Sponsor:   University of California, San Francisco
Not yet recruiting - verified February 2017

A Study to Investigate the Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension

Condition:   Portal Hypertension
Interventions:   Drug: FE 204205;   Drug: Placebo
Sponsor:   Ferring Pharmaceuticals
Recruiting - verified February 2017

Comprehensive Treatment of Angina in Women With Microvascular Dysfunction

Conditions:   Angina Pectoris;   Coronary Microvascular Disease
Interventions:   Dietary Supplement: Diet;   Behavioral: Training;   Drug: Medication (with statin and ACE-inhibition)
Sponsors:   Bispebjerg Hospital;   University Hospital Bispebjerg and Frederiksberg;   Cambridge Weight Plan Limited
Recruiting - verified February 2017

Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial

Conditions:   Congestive Heart Failure;   Heart Failure, Left-Sided;   Left-Sided Heart Failure
Interventions:   Drug: Albuterol;   Other: Saline placebo
Sponsor:   Mayo Clinic
Recruiting - verified February 2017

BAROSTIM THERAPY™ In Resistant Hypertension

Condition:   Hypertension
Intervention:   Device: Barostim Neo™ System
Sponsor:   CVRx, Inc.
Recruiting - verified February 2017

Evaluation of the Possibility to Delegate Glaucoma Surveillance to Orthoptists in Hospital

Condition:   Glaucoma
Intervention:   Other: Monitoring by an orthoptist then by an ophthalmologist
Sponsor:   Fondation Ophtalmologique Adolphe de Rothschild
Recruiting - verified February 2017

Moderato System: A Double-Blind Randomized Trial

Conditions:   Hypertension Resistant to Conventional Therapy;   Bradycardia;   Atrioventricular Block
Interventions:   Device: BackBeat-PHC ON;   Device: BackBeat-PHC OFF
Sponsors:   BackBeat Medical Inc;   MGH Echo Core Lab;   MLM Medical Labs GmbH;   nabios GmbH
Recruiting - verified February 2017

Preliminary Testing of the Vitaliti CVSM Wearable, Vitaliti Spirotoscope, and Vitaliti IVD Station

Conditions:   Urinary Tract Infection;   Diabetes Mellitus;   Atrial Fibrillation;   OSA;   COPD;   Pneumonia;   Acute Otitis Media;   Leukocytosis;   Iron Deficient Anemia;   Hypertension;   Healthy Volunteers
Intervention:   Device: Vitaliti
Sponsor:   Cloud DX Inc.
Enrolling by invitation - verified February 2017

Acupuncture Lowering Blood Pressure for Secondary Prevention of Stroke

Condition:   Cerebral Infarction
Intervention:   Device: acupuncture
Sponsors:   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine;   State Administration of Traditional Chinese Medicine of the People's Republic of China
Recruiting - verified February 2017

iPhone App Compared to Standard Riva-Rocci (RR)-Measurement During Stress Testing

Condition:   Blood Pressure
Interventions:   Device: cuff device;   Device: iphone
Sponsor:   University Hospital, Basel, Switzerland
Completed - verified February 2017

Effect of Elevated Intraocular Pressure in Glaucoma Patients During Femtolaser Cataract Surgery

Conditions:   Glaucoma;   Cataract
Interventions:   Procedure: Femtolaser surgery;   Procedure: Phacoemulsification
Sponsor:   Fondation Ophtalmologique Adolphe de Rothschild
Recruiting - verified February 2017

Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

Condition:   Hypertension, Pulmonary
Intervention:   Drug: Ventavis (Iloprost, BAYQ6256)
Sponsor:   Bayer
Recruiting - verified February 2017

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

Conditions:   Portal Hypertension;   Liver Cirrhosis
Interventions:   Drug: Ifetroban;   Drug: Placebo
Sponsor:   Cumberland Pharmaceuticals
Not yet recruiting - verified February 2017

Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer

Condition:   Colorectal Neoplasms
Interventions:   Drug: BI 695502;   Drug: chemotherapy
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension

Condition:   Pulmonary Arterial Hypertension
Intervention:   Drug: Anakinra
Sponsor:   Virginia Commonwealth University
Recruiting - verified February 2017

A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

Condition:   Hypertension, Pulmonary
Intervention:   Drug: Adempas (Riociguat, BAY63-2521)
Sponsor:   Bayer
Recruiting - verified February 2017

A Physical Activity Program in End-state Liver Disease

Conditions:   End-stage Liver Disease (ESLD);   Liver Transplant;   Sarcopenia;   Poor Physical Fitness;   Cirrhosis;   Portal Hypertension
Interventions:   Other: Nutritional consultation;   Behavioral: Physical training program;   Behavioral: Behavioral modification therapy
Sponsor:   University of Arkansas
Enrolling by invitation - verified February 2017

A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension

Conditions:   Open-Angle Glaucoma;   Ocular Hypertension
Interventions:   Drug: Fixed Combination;   Drug: Bimatoprost;   Drug: Timolol
Sponsor:   ForSight Vision5, Inc.
Completed - verified February 2017

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

Conditions:   Open-angle Glaucoma;   Ocular Hypertension
Interventions:   Drug: Brinzolamide 1%/Brimonidine 0.2% suspension;   Drug: Brinzolamide/Brimonidine vehicle;   Drug: Travoprost 0.004%/Timolol 0.5% solution
Sponsor:   Alcon Research
Recruiting - verified February 2017

Endtidal Ethanol in Sclerotherapy

Condition:   Ethanol Concentration
Intervention:   Device: Alcomed 3011®
Sponsor:   University Hospital Inselspital, Berne
Recruiting - verified February 2017

PADN to Treat Severe Obstructive Sleep Apnea

Condition:   Obstructive Sleep Apnea Syndrome
Interventions:   Procedure: Pulmonary Arterial Denervation;   Procedure: Sham procedure
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting - verified February 2017

A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults

Condition:   Pre-hypertension
Interventions:   Dietary Supplement: Neo40 Daily®;   Dietary Supplement: Placebo
Sponsors:   KGK Synergize Inc.;   Neogenis Laboratories
Active, not recruiting - verified February 2017

Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST

Condition:   Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Interventions:   Drug: Placebo capsules;   Drug: Bardoxolone methyl capsules
Sponsor:   Reata Pharmaceuticals, Inc.
Recruiting - verified February 2017

Chemical Renal Ethanol Sympatholysis Under CT Guidance Use for the Control of Therapy-Resistant Hypertension

Conditions:   Hypertension Resistant to Conventional Therapy;   Kidney Failure, Chronic
Interventions:   Procedure: Renal sympathicolysis;   Procedure: Ambulatory Blood Pressure Monitoring;   Radiation: Magnetic Resonance Angiography;   Biological: Blood test
Sponsor:   University Hospital, Grenoble
Recruiting - verified February 2017

Dexmedetomidine vs. Midazolam Sedation for Endobronchial Ultrasound

Conditions:   Conscious Sedation During Procedure;   Endobronchial Ultrasound
Interventions:   Drug: Dexmedetomidine;   Drug: Midazolam bolus;   Other: Saline placebo;   Drug: Rescue midazolam;   Drug: Fentanyl
Sponsor:   Postgraduate Institute of Medical Education and Research
Completed - verified February 2017

Postprandial Effects of a High Potassium Meal

Condition:   Hypertension
Interventions:   Other: High Potassium Meal;   Other: Low Potassium Meal
Sponsor:   Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Active, not recruiting - verified February 2017

Integrating Online Weight Management With Primary Care Support

Condition:   Obesity
Interventions:   Behavioral: Online weight management program;   Behavioral: Population health management support
Sponsors:   Brigham and Women's Hospital;   Patient-Centered Outcomes Research Institute
Recruiting - verified February 2017

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Conditions:   Pulmonary Hypertension;   Interstitial Lung Disease;   Combined Pulmonary Fibrosis and Emphysema
Intervention:   Drug: Inhaled Treprostinil
Sponsor:   United Therapeutics
Enrolling by invitation - verified February 2017

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Conditions:   Pulmonary Hypertension;   Interstitial Lung Disease;   Combined Pulmonary Fibrosis and Emphysema
Interventions:   Drug: Inhaled Treprostinil;   Drug: Placebo
Sponsor:   United Therapeutics
Recruiting - verified February 2017

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease

Condition:   Anemia
Interventions:   Drug: FG-4592;   Drug: Epoetin Alfa
Sponsor:   FibroGen
Active, not recruiting - verified February 2017

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

Condition:   Hypertension
Interventions:   Drug: telmisartan/amlodipine 40/5mg;   Drug: YH22162 40/5/12.5 mg;   Drug: telmisartan/amlodipine 80/5mg;   Drug: YH22162 80/5/25 mg;   Drug: telmisartan/amlodipine 40/5mg placebo;   Drug: YH22162 40/5/12.5 mg placebo;   Drug: telmisartan/amlodipine 80/5mg placebo;   Drug: YH22162 80/5/25 mg placebo
Sponsor:   Yuhan Corporation
Completed - verified February 2017

Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis

Conditions:   Renal Failure;   End Stage Renal Disease;   Hemodialysis;   Vascular Access
Interventions:   Biological: Human Acellular Vessel (HAV);   Device: ePTFE graft
Sponsors:   Humacyte, Inc.;   CTI Clinical Trial and Consulting Services
Recruiting - verified February 2017

Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension

Condition:   Essential Hypertension
Interventions:   Drug: ERA;   Drug: Lisinopril;   Other: Placebo
Sponsor:   Actelion
Active, not recruiting - verified February 2017

iPhone App Compared to Standard RR-measurement

Conditions:   Hypertension;   Blood Pressure
Interventions:   Device: cuff device (Omron HBP-1300-E Pro);   Device: iPhone 4s
Sponsors:   Jens Eckstein;   Preventicus GmbH
Completed - verified February 2017

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

Conditions:   Primary Open-Angle Glaucoma;   Ocular Hypertension
Intervention:   Drug: Bimatoprost Ocular Insert
Sponsor:   ForSight Vision5, Inc.
Completed - verified February 2017

Egypt Hypertension Study

Condition:   Different Classes of the Antihypertensive Treatment
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2017

Evaluation of the Heparin Binding Protein Levels in Sepsis

Conditions:   Sepsis;   Infection;   Septic Shock
Intervention:   Other: HBP lab test
Sponsor:   Christiana Care Health Services
Active, not recruiting - verified February 2017

Evaluation of Periop Biochemical Stress Factors in Craniotomy Neurosurgical Procedure With Respect to Preop Hypertension

Condition:   Perioperative Hypertension
Interventions:   Drug: atenolol;   Drug: lisinopril;   Other: glucose
Sponsor:   Milton S. Hershey Medical Center
Completed - verified February 2017

Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies

Condition:   Bronchopulmonary Dysplasia
Intervention:   Biological: Mesenchymal Stem Cell (MSC) therapy
Sponsors:   Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal;   Instituto de Salud Carlos III;   Fundación de Ayuda a la Investigación sobre la Hipertensión pulmonar
Not yet recruiting - verified February 2017

An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres

Conditions:   Stroke;   Prevention and Control;   Atrial Fibrillation
Intervention:   Drug: Direct Oral Anticoagulant (DOAC)
Sponsor:   Bayer
Completed - verified February 2017

Effects of Metoprolol and Amlodipine on Cardiac Remodeling, Arrhythmias and Blood Pressure Variation in Hypertensive Patients With Sleep Apnea Syndrome

Conditions:   Sleep Apnea Syndrome;   Hypertension
Interventions:   Drug: Amlodipine;   Drug: metoprolol
Sponsor:   First Affiliated Hospital of Harbin Medical University
Recruiting - verified October 2014

Optimizing Individual Nutrition in Preterm Very Low Birth Weight Infants

Conditions:   Infant, Premature, Diseases;   Infant, Small for Gestational Age
Interventions:   Dietary Supplement: Individualized Nutrition;   Dietary Supplement: Optimized nutrition
Sponsors:   University of Texas Southwestern Medical Center;   Children's Medical Center Dallas;   The Gerber Foundation
Recruiting - verified February 2017

Home-Based Screening for Early Detection of Atrial Fibrillation in Primary Care Patients Aged 75 Years and Older

Conditions:   Atrial Fibrillation;   Hypertension
Intervention:   Device: Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)
Sponsors:   Population Health Research Institute;   Canadian Stroke Prevention Intervention Network;   Canadian Institutes of Health Research (CIHR);   Heart and Stroke Foundation of Canada;   Canadian Stroke Network;   Boehringer Ingelheim;   iRhythm Technologies, Inc.;   Microlife
Recruiting - verified February 2017

A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation

Condition:   Hypertension, Pulmonary
Intervention:   Device: electrical pulsed plasma discharge synthesis of nitric oxide
Sponsor:   Massachusetts General Hospital
Completed - verified February 2017

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

Condition:   PAH
Intervention:   Drug: oral treprostinil
Sponsor:   United Therapeutics
Active, not recruiting - verified February 2017

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Chemotherapy;   Drug: BI 695502;   Drug: bevacizumab;   Drug: Chemotherapy
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

Condition:   Hypertension
Interventions:   Drug: Azilsartan Medoxomil;   Drug: Losartan;   Drug: Placebo for Azilsartan Medoxomil;   Drug: Placebo for Losartan
Sponsor:   Arbor Pharmaceuticals, Inc.
Recruiting - verified February 2017

Pulmonary Arterial Denervation in Patients With Pulmonary Arterial Hypertension Associated With the Left Heart Failure

Condition:   Pulmonary Hypertension
Interventions:   Procedure: Pulmonary arterial denervation;   Drug: Standard treatment
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting - verified February 2017

Long Term Outcomes of Venous Thromboembolism

Conditions:   Post Thrombotic Syndrome;   Chronic Thromboembolic Pulmonary Hypertension;   Venous Thrombosis
Intervention:  
Sponsor:   Ostfold Hospital Trust
Recruiting - verified February 2017

Dynamic Assessment of Right Ventricular Function With Inhaled Nitric Oxide During Cardiac MRI

Condition:   Pulmonary Vascular Disorder
Intervention:   Drug: INOmax Inhalation
Sponsors:   Vanderbilt University;   Mallinckrodt
Completed - verified February 2017

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2017

A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia

Condition:   Essential Hypertension, Dyslipidemia
Interventions:   Drug: Fimasartan and Rosuvastatin;   Drug: Fimasartan;   Drug: Rosuvastatin
Sponsor:   Boryung Pharmaceutical Co., Ltd
Completed - verified June 2014

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2017

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

Conditions:   Primary Open-Angle Glaucoma;   Ocular Hypertension
Intervention:   Drug: Bimatoprost Ocular Ring
Sponsor:   ForSight Vision5, Inc.
Completed - verified February 2017

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )

Condition:   Hypertension, Pulmonary
Intervention:   Drug: Riociguat (ADEMPAS, BAY63-2521)
Sponsor:   Bayer
Recruiting - verified February 2017

Registro Campania Salute Network on Hypertension

Condition:   Hypertension; Heart Disease, Hypertensive
Intervention:  
Sponsor:   Federico II University
Recruiting - verified February 2017

Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Threatened Miscarriage

Condition:   Pregnancy
Interventions:   Drug: Dydrogesterone;   Drug: Placebo
Sponsor:   The University of Hong Kong
Recruiting - verified February 2017

Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension

Conditions:   Complications; Cesarean Section;   Spinal Anesthetics Causing Adverse Effects in Therapeutic Use
Intervention:   Drug: Phenylephrine
Sponsor:   Wake Forest University Health Sciences
Withdrawn - verified February 2017

Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

Condition:   Pulmonary Hypertension
Interventions:   Drug: Macitentan;   Drug: Placebo
Sponsor:   Actelion
Completed - verified February 2017

Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

Condition:   Carcinoma, Hepatocellular
Interventions:   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Myfortic;   Drug: CellCept;   Drug: Imuran
Sponsor:   Baylor Research Institute
Recruiting - verified February 2017

Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Hypertension
Interventions:   Drug: Renal nerve denervation;   Device: Cryoablation
Sponsor:   Medtronic Atrial Fibrillation Solutions
Recruiting - verified February 2017

Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol

Condition:   Severe Pre-eclampsia, Postpartum Condition or Complication
Interventions:   Drug: misoprostol;   Drug: carbetocin
Sponsor:   khalid abd aziz mohamed
Completed - verified February 2017

Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia

Condition:   Preeclampsia
Interventions:   Biological: Recombinant human antithrombin (ATryn);   Other: Normal Saline 0.9%
Sponsor:   rEVO Biologics
Completed - verified February 2017

Novel Drug Delivery Technique Via Retroject Device

Condition:   Glaucoma
Interventions:   Device: Retroject Device;   Drug: ethacrynic acid injection;   Drug: balanced salt solution
Sponsor:   Molly Walsh
Completed - verified February 2017

Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension

Condition:   Chronic Thromboembolic Pulmonary Hypertension
Intervention:   Drug: Macitentan
Sponsor:   Actelion
Active, not recruiting - verified February 2017

Atrial Fibrillation Detected by Continuous ECG Monitoring

Conditions:   Atrial Fibrillation;   Stroke;   Hypertension;   Diabetes
Intervention:   Device: LOOP recorder (Medtronic LINQ device)
Sponsors:   Rigshospitalet, Denmark;   Bispebjerg Hospital;   Zealand University Hospital;   Odense University Hospital;   University of Southern Denmark;   Aalborg University
Active, not recruiting - verified February 2017

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Condition:   Persistent Pulmonary Hypertension of the Newborn
Interventions:   Drug: IV Remodulin;   Drug: Placebo
Sponsor:   United Therapeutics
Recruiting - verified February 2017

Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension

Condition:   Hypertension, Pulmonary
Intervention:   Drug: Iloprost (Ventavis, BAYQ6256)
Sponsor:   Bayer
Recruiting - verified February 2017

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified February 2017

Measurements of Doppler Signals Noninvasively From the Lung in Congestive Heart Failure

Condition:   Pulmonary Edema
Intervention:   Device: Transchoracic ultrasound Doppler
Sponsor:   Echosense Ltd.
Completed - verified August 2013

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis

Condition:   Anemia in Chronic Kidney Disease in Non-dialysis Patients
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   Astellas Pharma Europe B.V.;   FibroGen
Active, not recruiting - verified February 2017

Polygen Defi-Alpha: Genetic Polymorphisms Study in Children With Alpha-1 Antitrypsin Deficiency, Included in the DEFI-ALPHA Cohort

Condition:   Children With a Deficiency of Alpha-1 Antitrypsin
Intervention:   Other: blood sampling
Sponsor:   Hospices Civils de Lyon
Recruiting - verified February 2017

Evaluation of Lung Doppler Signals in Pulmonary Hypertension

Condition:   Pulmonary Hypertension
Intervention:  
Sponsors:   Echosense Ltd.;   Sheba Medical Center
Unknown status - verified April 2013

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

Condition:   Hypertension, Pulmonary
Interventions:   Drug: Tadalafil;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2017

A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

Condition:   Kidney Transplantation
Interventions:   Drug: Belatacept;   Drug: Tacrolimus;   Drug: Cyclosporine
Sponsor:   Bristol-Myers Squibb
Recruiting - verified June 2016

Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients

Condition:   Pulmonary Arterial Hypertension
Intervention:   Drug: Ventavis (Iloprost, BAYQ6256)
Sponsor:   Bayer
Completed - verified February 2017

Hormonal, Metabolic, and Signaling Interactions in PAH

Conditions:   Idiopathic Pulmonary Arterial Hypertension;   Heritable Pulmonary Arterial Hypertension;   Scleroderma Associated Pulmonary Arterial Hypertension;   Appetite Suppressant Associate PAH
Intervention:  
Sponsor:   Vanderbilt University
Recruiting - verified February 2017

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

Condition:   Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions:   Drug: placebo;   Drug: iv sildenafil
Sponsor:   Pfizer
Recruiting - verified February 2017

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: Dulaglutide;   Drug: Insulin glargine;   Drug: Insulin lispro
Sponsor:   Eli Lilly and Company
Completed - verified February 2017

Study of a Holistic Health Program for United Methodist Clergy

Conditions:   Obesity;   Depression;   Diabetes;   Hypertension;   Hypercholesterolemia
Intervention:   Behavioral: Holistic health
Sponsors:   Duke Clergy Health Initiative;   The Duke Endowment
Completed - verified February 2017

Telehealth & Remote Measurement Technologies to Improve Medication Adherence in Hypertension

Condition:   Hypertension
Interventions:   Behavioral: Computer Controlled Telephone Counseling;   Other: Physician information and management recommendations
Sponsor:   Boston Medical Center
Completed - verified February 2017

TRANSforming InTerprofessional Cardiovascular Prevention in Primary Care

Conditions:   Diabetes Mellitus, Type 2;   Hypertension;   Dyslipidemias;   Cholesterol, LDL;   Comorbitdity
Interventions:   Other: Facilitation;   Other: Passive diffusion
Sponsors:   Fonds de la Recherche en Santé du Québec;   Université de Montréal
Completed - verified February 2017

Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)

Condition:   Peripheral Arterial Disease
Interventions:   Behavioral: Supervised Treadmill Exercise Therapy;   Other: Health education sessions (Control);   Drug: granulocyte macrophage colony stimulating factor (GM-CSF)
Sponsors:   Northwestern University;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified February 2017

Prediction and Prevention of Preeclampsia by First Trimester Ultrasound

Condition:   Preeclampsia
Intervention:  
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital
Completed - verified February 2017

Lifestyle Modification and Blood Pressure Study

Condition:   High Blood Pressure
Interventions:   Behavioral: Yoga exercise program;   Behavioral: Blood pressure education/walking program
Sponsor:   University of Pennsylvania
Completed - verified February 2017

A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Condition:   Essential Hypertension
Interventions:   Drug: Fimasartan 60 mg group;   Drug: Fimasartan 120 mg group;   Drug: Reference (Valsartan 80 mg) group
Sponsors:   Boryung Pharmaceutical Co., Ltd;   Seoul National University Hospital;   Kyungpook National University;   Catholic Medical Center;   Inje University;   Chonnam National University Hospital
Completed - verified December 2010

BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

Condition:   Pulmonary Hypertension
Intervention:   Drug: Riociguat (Adempas, BAY63-2521)
Sponsor:   Bayer
Active, not recruiting - verified February 2017

Functional and Cognitive Impairment in Advanced Kidney Disease

Condition:   Kidney Insufficiency, Chronic
Intervention:  
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified February 2017

Effect of CPAP on Blood Pressure in Patients With Sleep Apnea and Refractory Hypertension

Conditions:   Obstructive Sleep Apnea;   Refractory Arterial Hypertension
Interventions:   Device: CPAP;   Device: Control
Sponsors:   Corporacion Parc Tauli;   Carlos III Health Institute
Completed - verified February 2017

Mild Preeclampsia Near Term: Deliver or Deliberate?

Condition:   Preeclampsia
Intervention:   Procedure: Delivery of infant
Sponsor:   University of Mississippi Medical Center
Completed - verified November 2008

Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

Condition:   Hypertension, Pulmonary
Intervention:   Drug: Riociguat (Adempas, BAY63-2521)
Sponsor:   Bayer
Active, not recruiting - verified February 2017

Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure

Condition:   Portal Hypertension
Interventions:   Drug: NCX-1000;   Drug: Placebo
Sponsor:   Forest Laboratories
Terminated - verified February 2017

Maternal and Umbilical Cord Hormone Concentrations in Twin and Singleton Pregnancies

Condition:   Normal Pregnancy
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Completed - verified January 25, 2017

Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging

Conditions:   Macular Degeneration;   Glaucoma;   Diabetic Retinopathy
Intervention:  
Sponsors:   New York University School of Medicine;   National Eye Institute (NEI)
Active, not recruiting - verified February 2017